Please ensure Javascript is enabled for purposes of website accessibility

Why Solid Biosciences Stock Is Sinking Today

By Keith Speights - Jan 8, 2021 at 11:57AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Blame it on Sarepta.

What happened

Shares of Solid Biosciences (SLDB 1.58%) were moving 15.9% lower as of 11:29 a.m. EST on Friday. The drop came after Sarepta Therapeutics (SRPT 2.76%) reported disappointing clinical results for experimental gene therapy SRP-9001 in treating rare genetic disease Duchenne muscular dystrophy (DMD). Solid's leading pipeline candidate, SGT-001, is also a gene therapy targeting DMD.

So what

Sarepta's problem was that SRP-9001 didn't meet the primary functional endpoint of its clinical study. That endpoint was a statistically significant improvement in score on the North Star Ambulatory Assessment (NSAA), a scale used to assess the functional motor abilities in children with DMD.

Duchenne muscular dystrophy printed over a bar code with pipettes behind the bar code label

Image source: Getty Images.

Just because SRP-9001 failed in a clinical study doesn't necessarily mean that SGT-001 will. However, Solid's SGT-001 uses the same approach for treating DMD that SRP-9001 does. It transfers microdystrophin, a synthetic version of the dystrophin-producing gene, into the cells of a DMD patient in hopes to restore muscle function. DMD is caused by a mutation in the gene that encodes the protein dystrophin.

Sarepta appears to believe that the randomization process with its clinical study could be the culprit. Patients in the study ages 4 and 5 did achieve statistically significant functional improvement, while those ages 6 and 7 didn't. Sarepta CEO Doug Ingram said that "the randomization process resulted in a significant imbalance in baseline NSAA scores between the active and placebo cohorts of the participants ages 6-7, making the 6-7 age groups non-comparable and likely substantially contributing to the inability to achieve statistical significance."

Now what

It's understandable that Solid Biosciences would be weighed down by Sarepta's news. However, the most important thing for the biotech stock is Solid's own clinical testing. The company plans to resume dose in its phase 1/2 clinical study of SGT-001 soon after the U.S. Food and Drug Administration lifted a clinical hold on the trial in October. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Solid Biosciences Inc. Stock Quote
Solid Biosciences Inc.
SLDB
$0.55 (1.58%) $0.01
Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
SRPT
$71.13 (2.76%) $1.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.